[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Roflumilast, a new inhibitor of phosphodiesterase 4, showed moderate efficacy in clinical trials with patients suffering from chonic obstructive pulmonary disease (COPD). Improvement of pulmonary function is predominantly attributed to antiinflammatory effects with decrease in mucus secretion and less exacerbations. Diarrhoea, headache and nausea are typical adverse events.
Kreutzkamp
Barbara
B
barkreutz@t-online.de
D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003521:Cyclopropanes / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011788:Quality of Life; D012129:Respiratory Function Tests
D000631:Aminopyridines; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast